Hematological Monitoring
Hematological Monitoring - Related Videos
11:08
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
0 Views •
Cited by 52 •
2012
A method to culture an endothelial cell monolayer throughout the entire inner 3D surface of a microfluidic device with microvascular-sized channels (<30 μm) is described. This in vitro microvasculature model enables the study of biophysical interactions between blood cells, endothelial cells, and soluble factors in hematologic diseases.
23:56
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
0 Views •
Cited by 4 •
2010
Anti-retroviral therapy to treat HIV/AIDS is monitored in South Africa on a large scale. Flow cytometry is combined for haematology (CD45), immunology (CD4) and viral-load linked CD38 assay. Recorded at NHLS-SA laboratories, Johannesburg, these modern methods are cost-efficient with heightened local internal quality control, serving as role-models for resource-limited diagnostics.
08:29
Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
0 Views •
Cited by 29 •
2012
We describe a rat model of post traumatic stress disorder (PTSD) that reveals the persistent alterations in neuroendocrine function and the delayed long-term, exaggerated fear response, characteristic of PTSD patients. The animal model and methods described here are useful for correlating biomarkers in brain nuclei, which are mechanistic but cannot be measured in patients, with biomarkers in peripheral white blood cells, which can.
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
0 Views •
Cited by 10 •
2019
We describe a quantitative real-time in vitro cytolysis assay system to evaluate the potency of chimeric antigen receptor T cells targeting liquid and solid tumor cells. This protocol can be extended to assess other immune effector cells, as well as combination treatments.
02:05
Self-Presentation: Self-Monitoring and Self-Handicapping
0 Views •
2020
People can go to great lengths to protect their self-image and present themselves in ways that they want others to see them. Sociologist Erving Goffman presented the idea that a person is like an actor on a stage. Calling his theory dramaturgy, Goffman believed that we use “impression management” to present ourselves to others as we hope to be perceived. Each situation is a new scene, and individuals perform different roles depending on who is present (Goffman, 1959). Think about the way you...
FAQs
Comparing measurements over time can reveal clinically important changes that a single result may not show. Hematological monitoring evaluates new findings against both reference ranges and the patient’s previous measurements, helping distinguish a stable pattern from a developing abnormality. This trend-based approach supports earlier recognition of changes in blood counts, hemoglobin, platelets, or clotting function.
Each measurement category reflects a different aspect of blood status. Blood cell counts and differential counts provide information about circulating cells, hemoglobin relates to oxygen-carrying status, platelet results help assess bleeding-related concerns, and clotting tests evaluate coagulation function. Reviewing these findings together gives clinicians a broader basis for identifying abnormalities and planning care.
The pattern and direction of laboratory changes can help identify concerns such as anemia, infection, bleeding risk, bone marrow dysfunction, or treatment-related toxicity. Interpretation depends on comparing results with reference ranges and earlier measurements rather than considering an isolated value alone. This context helps clinicians recognize which findings may require closer observation or a change in management.
The process generally begins with serial blood sampling, followed by laboratory analysis using a complete blood count, differential count, and appropriate coagulation tests. Results are then reviewed against reference ranges and the patient’s prior measurements. Repeating this workflow over time allows clinicians to track changes, identify clinically important patterns, and use the findings to guide medical decisions.
It is particularly important when care may alter blood counts, coagulation, or bleeding risk. The overview identifies chemotherapy, anticoagulants, and transfusions as key settings. Monitoring can reveal treatment-related toxicity or other clinically important changes, supporting timely adjustment of care and helping clinicians use these treatments more safely.
Results provide objective information about whether blood-related changes are emerging during treatment. During chemotherapy, they can reveal treatment-related toxicity; with anticoagulants, coagulation findings help assess clotting function; and around transfusions, blood measurements help track clinically important changes. Clinicians can use these findings, together with prior results and reference ranges, to adjust care when needed.